CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who have failed oxaliplatin-based first-line treatment.
Metastatic Colorectal Cancer
DRUG: CS-1008|DRUG: irinotecan
Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone., 1 year
Determine the difference in overall survival for CS-1008 administered in combination with irinotecan and irinotecan alone., 1 year|Determine the difference in median survival for CS-1008 administered in combination with irinotecan and irinotecan alone., 1 year|Determine the difference in objective response rate (ORR) for CS-1008 administered in combination with irinotecan and irinotecan alone., 1 year|To determine the Incidence of anti- CS-1008 antibody formation., 1 year
The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who have failed oxaliplatin-based first-line treatment.